Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer
- Journal:
- Science Translational Medicine
- Published:
- Affiliations:
- 6
- Authors:
- 14
| Institutions | Authors | Share |
|---|---|---|
| University of Southern Denmark (SDU), Denmark | 0.69 | |
| Garvan Institute of Medical Research, Australia | 0.14 | |
| University of New South Wales (UNSW Sydney), Australia | 0.14 | |
| Odense University Hospital (OUH), Denmark | 0.02 |